Bibliografia

1. Andreasen N. et al. Negative *positive schizophrenia. Arch Gen Psychiatry 1982;39:789-794.

2. Lincoln TM. and Hodgins S. Is lack of insight associated with physically aggressive behavior among people with schizophenia living in the community? The Jor of Nervous and Mental Disease 2008;196(1):62-66.

3. Burns T. and Bale R. Clinical advantages of amisulpride in the treatment of acute Schizofrenia. J Int Med Res; 29(6):451-66.2001.

4. NussP, Hummer M & Tessier C. The use of amisulpride in the treatment of acute psychosis. Ther Clin Risk Management 2007;3(1):3-11.

5. Davis J, Chen and Ira D. A Meta-analysis of the ecacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60:553-564.

6. Sanofi-aventis. Solian® Información Para Prescribir Amplia. México 2007.

7. Mortimer AM. How do we choose between atypical antipsychotics? The advantages of amisulpride. Int J Neuropsychopharmacol; 7(Suppl 1): S21–25.2004.

8. Boyer P. et al. Amisulpride versus amineptine and placebo for the treatment of dysthymia. Neuropsychobiology; 39(1):25–32.1999.

9. Peuskens J. et al.Treatment of cognitive dysfuntion in Clinic Therapeutics 2005.27(A):S25-S37.

10. Peuskens J. et al. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur Neuropsychopharmacol; 12(4):305–310.2002.

11. Leucht S, et. al. A Meta-Analysis of Head-to-Head Comparisons of Second-Generation Antipsychotics in the Treatment of Schizophrenia. Am J Psychiatry, February 2009;166(2):152-163.

12. Taylor DM and McAskill R. Atypical antipsychotics and weight gain a systematic review. Acta Psychiatr Scand 2000;101(6):416-4.

13. Allison D. et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. AM J Psychiatry 1999;156:1636-1696.

14. Burns T, et al. Switching antipsychotic medications: general recommendations and switching to amisulpride. Curr Med Res Opinion 2002;18(4):201–208.

15. Linden M, et al. Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride. Jour Psychophar 2006;20(6):815–823.

16. Lerner V. et al. Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy. Clin Neuropharmacol 2005;28(2):66–71